ArticleBMC pregnancy and childbirth2025
Combined vaginal progesterone and cervical Pessary effect on preterm birth in Singleton pregnancies with short cervix: a retrospective cohort study.
Article in BMC pregnancy and childbirth, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundTo determine whether the combination of vaginal progesterone and cervical pessary initiated during the second trimester reduces the incidence of preterm birth and enhance neonatal outcomes among women diagnosed with singleton pregnancies and a short cervix. STUDY
designWe conducted a retrospective cohort study involving 322 pregnant individuals with singleton gestations and a sonographically confirmed short cervix (≤ 25 mm), managed at Akbarabadi Hospital, a tertiary referral center. Participants were allocated into two treatment groups: one received both vaginal progesterone (200 mg daily) and an Arabin cervical pessary, and the other received progesterone alone. Primary outcomes included the incidence of spontaneous preterm birth before 34 and 37 weeks of gestation. Secondary outcomes encompassed neonatal morbidity, NICU admission, birth weight, and maternal complications. Comparative analyses were conducted using Cox proportional hazards regression and standard statistical tests, with adjustments for potential confounders.
resultsPreterm birth before 34 weeks was significantly lower in the combination group (3.1%) compared to the progesterone-only group (12.4%; p = 0.002). Similarly, births before 37 weeks were reduced (22.4% vs. 37.3%; p = 0.003). The combination group showed better neonatal outcomes, including fewer NICU admissions (34.8% vs. 54.0%; p = 0.012), shorter NICU stays were more frequent in the combination group (66% discharged within 3 days vs. 34% in progesterone-only group; p = 0.012), and a lower need for resuscitation (5.6% vs. 12.4%; p = 0.032). Maternal complications (including postpartum hemorrhage, infection, and ICU admissions) were noticeably lower in the combination group (2.5% vs. 10.6%; p = 0.003).
conclusionCombining vaginal progesterone with a cervical pessary during mid-pregnancy can significantly reduce the risk of preterm birth and improve outcomes for both mother and baby in singleton pregnancies with a short cervix. These findings support incorporating dual therapy into clinical practice guidelines as an effective approach to preventing preterm birth in high-risk populations. These findings suggest that dual therapy may reduce preterm birth risk, but confirmation in prospective randomized trials is warranted.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.